DE69818698T2 - Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese - Google Patents

Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese Download PDF

Info

Publication number
DE69818698T2
DE69818698T2 DE69818698T DE69818698T DE69818698T2 DE 69818698 T2 DE69818698 T2 DE 69818698T2 DE 69818698 T DE69818698 T DE 69818698T DE 69818698 T DE69818698 T DE 69818698T DE 69818698 T2 DE69818698 T2 DE 69818698T2
Authority
DE
Germany
Prior art keywords
mmol
compounds
compound
zinc
pathological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69818698T
Other languages
German (de)
English (en)
Other versions
DE69818698D1 (de
Inventor
Vincenzo Politi
Enrico Gavuzzo
Carlo Gallina
Giovanni Di Stazio
Silvana D'alessio
Antonio Sella
Cinzia Piazza
Cesare Giordano
Barbara Gorini
Gabriella Panini
Mario Paglialunga Paradisi
Maurizio Cirilli
Giorgio Pochetti
Fernando Mazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polifarma SpA
Consiglio Nazionale delle Richerche
Original Assignee
Polifarma SpA
Consiglio Nazionale delle Richerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma SpA, Consiglio Nazionale delle Richerche filed Critical Polifarma SpA
Publication of DE69818698D1 publication Critical patent/DE69818698D1/de
Application granted granted Critical
Publication of DE69818698T2 publication Critical patent/DE69818698T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69818698T 1997-07-17 1998-07-17 Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese Expired - Fee Related DE69818698T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM970441 1997-07-17
IT97RM000441A IT1296305B1 (it) 1997-07-17 1997-07-17 Inibitori di metalloproteinasi loro uso terapeutico e procedimento per la produzione del composto di partenza nella loro
PCT/IT1998/000202 WO1999003878A2 (en) 1997-07-17 1998-07-17 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis

Publications (2)

Publication Number Publication Date
DE69818698D1 DE69818698D1 (de) 2003-11-06
DE69818698T2 true DE69818698T2 (de) 2004-08-19

Family

ID=11405183

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69818698T Expired - Fee Related DE69818698T2 (de) 1997-07-17 1998-07-17 Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese

Country Status (8)

Country Link
US (1) US6339160B1 (enExample)
EP (1) EP1019434B1 (enExample)
JP (1) JP3325017B2 (enExample)
AU (1) AU8241898A (enExample)
DE (1) DE69818698T2 (enExample)
ES (1) ES2206955T3 (enExample)
IT (1) IT1296305B1 (enExample)
WO (1) WO1999003878A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6683165B1 (en) 1999-04-13 2004-01-27 Genome Therapeutics Corporation Human gene relating to respiratory diseases and obesity
GB9922577D0 (en) * 1999-09-23 1999-11-24 Center For Clinical & Basic Re Substituted phosphinate based peptide derivatives
WO2001078894A2 (en) * 2000-04-13 2001-10-25 Schering Corporation Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
US7364719B2 (en) * 2002-10-04 2008-04-29 The United States Of America As Represented By The Department Of Health And Human Services Vasoregulating compounds and methods of their use
AU2003295422B2 (en) * 2002-11-07 2009-01-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
BRPI0400284A (pt) * 2004-03-18 2005-11-01 Fundacao Oswaldo Cruz Uso de dm 43 e seus fragmentos como inibidor de metaloproteases de matriz
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
GB0708507D0 (en) * 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401963A1 (en) 1989-04-13 1990-12-12 Beecham Group p.l.c. Phosphonopeptides with collagenase inhibiting activity
IT1242002B (it) * 1990-10-03 1994-02-02 Polifarma Spa Composti con attivita' farmacologica antiipertensiva, analgesica, immunomodulante e antiinfiammatoria, che presentano nella molecola una sequenza di tre radicali, essendo alfa-amminoacido quello centrale
IT1277904B1 (it) * 1995-08-07 1997-11-12 Polifarma Spa Metodo per determinare l'attivita' terapeutica di composti inibitori di metalloproteinasi, nuovi composti inibitori, e loro impiego

Also Published As

Publication number Publication date
IT1296305B1 (it) 1999-06-25
AU8241898A (en) 1999-02-10
ITRM970441A0 (enExample) 1997-07-17
ITRM970441A1 (it) 1999-01-17
EP1019434B1 (en) 2003-10-01
WO1999003878A3 (en) 1999-04-01
JP3325017B2 (ja) 2002-09-17
WO1999003878A2 (en) 1999-01-28
JP2001525315A (ja) 2001-12-11
DE69818698D1 (de) 2003-11-06
US6339160B1 (en) 2002-01-15
EP1019434A2 (en) 2000-07-19
ES2206955T3 (es) 2004-05-16

Similar Documents

Publication Publication Date Title
DE60112079T2 (de) Vebindungen zur modulation des rage-rezeptors
DE69925268T2 (de) Dipeptid-Caspase-Inhibitoren und deren Verwendung
DE69532113T2 (de) Pyrimidin-derivate als interleukin inhibitoren
EP0635008B1 (de) Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren
DE69133385T2 (de) Verbesserte matrixmetallproteaseinhibitoren
DE69025952T2 (de) Antithrombotische peptide und pseudopeptide
DE69833654T2 (de) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
DE69531990T2 (de) Bicyclischer lactaminhibitor des interleukin-1-beta-konvertierenden enzyms
DE3881489T2 (de) Peptide mit collagenase hemmender wirkung.
CH649561A5 (en) Agmatine derivatives with anticoagulant effect and process for their preparation
DE69832268T2 (de) Peptidyl2-amino-1hydroxyalkansulfonsäuren als zysteinprotease-inhibitoren
DE69432573T2 (de) Inhibitoren des Endothelin konvertierenden Enzyms
DE3508251A1 (de) Dipeptide
DE602004012777T2 (de) 2-hydroxytetrahydrofuranderivate und ihre verwendung als arzneimittel
DE69635977T2 (de) Verfahren zur Bestimmung der therapeutischen Wirkung von Metalloproteinase-Verbindungen, neue Inhibitor-Verbindungen und deren therapeutische Verwendung
EP1272458A1 (de) Arginin-mimetika als faktor xa-inhibitoren
DE69426897T2 (de) Antithrombotisch wirkende azacycloalkyl-alkanoyl-peptide und-pseudopeptide
EP1019434B1 (en) Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis
DE69634955T2 (de) Tripeptidylpeptidase-inhibitoren
AT390619B (de) Verfahren zur herstellung von neuen prolinderivaten
EP1483285A1 (de) HEMMSTOFFE DES GERINNUNGSFAKTORS Xa, IHRE HERSTELLUNG UND VERWENDUNG
DE69913996T2 (de) Depsipeptide, die nicht-natürliche Aminosäuren enthalten
DE2601820A1 (de) Kathepsin d-inhibitoren
DE3222779C2 (enExample)
DE2063996B2 (de) alpha-Aminoxyhydroxamsäurederivate, Verfahren zur Herstellung derselben und diese enthaltende Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee